White matter integrity differences associated with post-traumatic stress disorder are not normalized by concurrent marijuana use.
Adolescent
Adult
Anisotropy
Brain
/ diagnostic imaging
Comorbidity
Cross-Sectional Studies
Diffusion Tensor Imaging
/ methods
Humans
Male
Marijuana Use
/ epidemiology
Middle Aged
Nerve Net
/ diagnostic imaging
Stress Disorders, Post-Traumatic
/ diagnostic imaging
White Matter
/ diagnostic imaging
Young Adult
Addiction
Diffusion tensor imaging
Fractional anisotropy
Marijuana
PTSD
Journal
Psychiatry research. Neuroimaging
ISSN: 1872-7506
Titre abrégé: Psychiatry Res Neuroimaging
Pays: Netherlands
ID NLM: 101723001
Informations de publication
Date de publication:
30 01 2020
30 01 2020
Historique:
received:
27
08
2019
revised:
12
11
2019
accepted:
13
11
2019
pubmed:
25
11
2019
medline:
1
9
2020
entrez:
25
11
2019
Statut:
ppublish
Résumé
Marijuana (MJ) use and post-traumatic stress disorder (PTSD) have both been associated with abnormalities in brain white matter tracts, including the cingulum and the anterior thalamic radiations (ATR), which project from subcortical regions to frontal cortex. Studies have not assessed the integrity of these tracts in patients with comorbid PTSD and MJ use. To examine effects of PTSD and MJ use on brain structure, we performed diffusion tensor imaging scans on seventy-two trauma-exposed participants, categorized into four groups: those with PTSD who used MJ at least weekly (PTSD+MJ; n = 20), those with PTSD with no regular MJ use (PTSD; n = 19), trauma-exposed controls without PTSD who used MJ (TEC+MJ; n = 14) and trauma-exposed controls with no PTSD or MJ use (TEC; n = 19). White matter integrity was evaluated by calculating fractional anisotropy (FA). Results showed that while FA values in the right ATR and the cingulum differed across groups, there were no significant interactions between PTSD and MJ in any white matter tracts, indicating that MJ exposure neither normalizes nor worsens white matter abnormalities in those with PTSD. Further study is needed to evaluate the impact of MJ use on other neurobiological markers of PTSD.
Identifiants
pubmed: 31760337
pii: S0925-4927(19)30238-0
doi: 10.1016/j.pscychresns.2019.111017
pmc: PMC7730843
mid: NIHMS1646666
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
111017Subventions
Organisme : NIDA NIH HHS
ID : K01 DA034093
Pays : United States
Organisme : NIDA NIH HHS
ID : K24 DA030443
Pays : United States
Organisme : NIDA NIH HHS
ID : R01 DA042043
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.
Références
Top Magn Reson Imaging. 2006 Aug;17(4):265-74
pubmed: 17415000
Neurotherapeutics. 2007 Jul;4(3):316-29
pubmed: 17599699
Depress Anxiety. 2010 Feb;27(2):190-211
pubmed: 20099273
Psychopharmacology (Berl). 2014 Apr;231(8):1455-65
pubmed: 24190588
J Trauma Stress. 2015 Dec;28(6):489-98
pubmed: 26606250
J Neuropsychiatry Clin Neurosci. 2012 Spring;24(2):223-36
pubmed: 22772671
IEEE Trans Med Imaging. 2001 Jan;20(1):70-80
pubmed: 11293693
Front Aging Neurosci. 2014 Sep 25;6:261
pubmed: 25309437
Prim Care Companion CNS Disord. 2015 May 07;17(3):
pubmed: 26644963
Psychoneuroendocrinology. 2015 Jan;51:567-76
pubmed: 25465169
Eur Child Adolesc Psychiatry. 2016 Aug;25(8):869-78
pubmed: 26700102
Curr Psychiatry Rep. 2012 Jun;14(3):197-202
pubmed: 22460663
Nat Neurosci. 2003 Jul;6(7):750-7
pubmed: 12808459
Arch Gen Psychiatry. 1998 Oct;55(10):913-7
pubmed: 9783562
Drug Alcohol Depend. 1996 Sep;42(1):49-54
pubmed: 8889403
Neurotoxicol Teratol. 2009 Nov-Dec;31(6):349-55
pubmed: 19631736
Ment Health Clin. 2018 Mar 26;8(2):86-94
pubmed: 29955551
Am Fam Physician. 2003 Dec 15;68(12):2401-8
pubmed: 14705759
Front Neuroinform. 2011 Oct 14;5:23
pubmed: 22016733
Psychiatry Res. 2013 Dec 30;214(3):260-8
pubmed: 24074963
J Child Psychol Psychiatry. 2009 Aug;50(8):943-51
pubmed: 19457047
Brain. 2012 Jul;135(Pt 7):2245-55
pubmed: 22669080
Ann N Y Acad Sci. 2010 Oct;1208:82-9
pubmed: 20955329
Cortex. 2015 Mar;64:249-59
pubmed: 25522360
Neuroimage. 1999 Feb;9(2):179-94
pubmed: 9931268
Psychiatry Res. 2008 Apr 15;162(3):256-61
pubmed: 18296031
Pediatr Neurol. 2017 Jan;66:12-20
pubmed: 27789118
J Clin Exp Neuropsychol. 2001 Dec;23(6):718-28
pubmed: 11910539
Hum Brain Mapp. 2018 Mar;39(3):1327-1338
pubmed: 29265681
Neuroimage. 2008 Jul 1;41(3):1067-74
pubmed: 18424082
Harm Reduct J. 2006 May 09;3:17
pubmed: 16684342
Dev Cogn Neurosci. 2015 Dec;16:23-35
pubmed: 26602958
Subst Use Misuse. 2010 Sep;45(11):1787-808
pubmed: 20590400
Brain Res. 2011 Sep 9;1411:98-107
pubmed: 21813114
Neuroimage. 2006 Jul 1;31(3):968-80
pubmed: 16530430
Neuroimage. 2011 Jan;54 Suppl 1:S62-8
pubmed: 20483375
Depress Anxiety. 2006;23(1):17-25
pubmed: 16247760
Brain Imaging Behav. 2018 Jun;12(3):870-881
pubmed: 28676987
Trends Neurosci. 1999 Jul;22(7):310-6
pubmed: 10370255
Brain Cogn. 2010 Apr;72(3):347-54
pubmed: 19932550
Psychiatry Res. 2006 Apr 30;146(3):231-42
pubmed: 16545552
Neuropsychopharmacology. 2012 Nov;37(12):2740-6
pubmed: 22871912
Depress Anxiety. 2013 Mar;30(3):207-16
pubmed: 23319445
Depress Anxiety. 2012 Oct;29(10):833-42
pubmed: 22941845
Acta Neuropsychiatr. 2012 Feb;24(1):34-42
pubmed: 25288457
Brain Res Cogn Brain Res. 2005 Apr;23(1):107-18
pubmed: 15795138
J Neurosci. 2010 Jun 2;30(22):7466-72
pubmed: 20519521
Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16913-8
pubmed: 25385625
Neuroimage Clin. 2018 May 16;19:581-598
pubmed: 29984166
Pediatrics. 2006 Jun;117(6):2093-100
pubmed: 16740852
Neurocase. 2007 Oct;13(5):402-10
pubmed: 18781439
Hum Brain Mapp. 2016 Apr;37(4):1486-511
pubmed: 26848101
J Psychiatr Res. 2009 Jan;43(3):189-204
pubmed: 19111160
Am J Epidemiol. 2002 Jun 1;155(11):988-96
pubmed: 12034577
Nat Rev Neurosci. 2011 Mar;12(3):154-67
pubmed: 21331082